

Monitoring the effect of oxytocin on the neural sensitivity to emotional faces via frequency-tagging EEG: a double-blind, cross-over study

Stephanie Van der Donck^{a,b}, Matthijs Moerkerke^{a,b}, Tereza Dlhosova^c, Sofie Vettori^{a,b}, Milena Dzhelyova^d, Kaat Alaerts^{b,e,*}, Bart Boets^{a,b,*}

^a Center for Developmental Psychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium

^b Leuven Autism Research (LAuRes), KU Leuven, Leuven, Belgium

^c Department of psychology, Faculty of Arts, Masaryk University, Brno, Czech republic

^d Institute of Research in Psychological Sciences, Institute of Neuroscience, Université de Louvain, Louvain-La-Neuve, Belgium

^e Neurorehabilitation Research Group, Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium

* Kaat Alaerts and Bart Boets are shared last authors

Short title: Oxytocin effect on the neural sensitivity to emotional faces

Corresponding author

Stephanie Van der Donck

Kapucijnenvoer 7 blok h - box 7001

3000 Leuven, Belgium

stephanie.vanderdonck@kuleuven.be

+32 16 32 55 11

26 Abstract

27 The neuropeptide oxytocin (OXT) is suggested to exert an important role in human social behaviors by
28 modulating the salience of social cues. To date, however, there is mixed evidence whether a single dose
29 of OXT can improve the behavioral and neural sensitivity for emotional face processing. To overcome
30 difficulties encountered with classic event-related potential studies assessing stimulus-saliency, we
31 applied frequency-tagging EEG to implicitly assess the effect of a single dose of OXT (24 IU) on the neural
32 sensitivity for positive and negative facial emotions. Neutral faces with different identities were
33 presented at 6 Hz, periodically interleaved with an expressive face (angry, fearful, and happy, in separate
34 sequences) every fifth image (i.e. 1.2 Hz oddball frequency). These distinctive frequency tags for neutral
35 and expressive stimuli allowed direct and objective quantification of the neural expression-
36 categorization responses. The study involved a double-blind, placebo-controlled, cross-over trial with
37 31 healthy adult men. Contrary to our expectations, we did not find an effect of OXT on facial emotion
38 processing, neither at the neural, nor at the behavioral level. A single dose of OXT did not evoke social
39 enhancement in general, nor did it affect social approach-avoidance tendencies. Possibly ceiling
40 performances in facial emotion processing might have hampered further improvement.

41

42 1. Introduction

43 Being able to quickly and adequately read faces and facial expressions is a key component for successful
44 everyday social interactions, as it allows for understanding one's feelings, reactions and intentions
45 (Elfenbein & Ambady, 2002). Moreover, proficient recognition of emotional faces has been found to be
46 related to more prosocial behavior (Kaltwasser et al., 2017).

47 An important biological modulator of social behavior and socio-cognitive processes is endogenous
48 oxytocin (OXT; MacDonald & MacDonald, 2010). OXT is a neuropeptide that is produced in the
49 hypothalamus and functions as a hormone and neuromodulator (Wigton et al., 2015). Central OXT levels
50 can, however, be manipulated by administering exogenous OXT (Martins et al., 2020). Extensive animal
51 research has demonstrated the potential of exogenous OXT in modulating social behavior when
52 delivered directly to the brain (for a review, see Quintana et al., 2018), which encouraged numerous
53 researchers over the past decades to study its effect on human sociality. The effects of intranasally
54 administered OXT on social functioning have increasingly been investigated in neurotypical populations,
55 as well as in psychiatric conditions that are characterized by social difficulties (Keech et al., 2018;
56 Kendrick et al., 2018; Peled-Avron et al., 2020), such as anxiety disorders (Naja & Aoun, 2017),
57 schizophrenia (Shilling & Feifel, 2016) and autism spectrum disorder (Guastella & Hickie, 2016). Despite
58 mixed results, generally, the findings summarized in these reviews suggest the effectiveness of
59 exogenous OXT to ameliorate social symptoms (Guastella & Hickie, 2016; Naja & Aoun, 2017; Shilling &
60 Feifel, 2016).

61 Mechanistic models suggest that OXT may exert its complex social effects by regulating the saliency of
62 social cues and/or by modulating (social) stress and anxiety (Churchland & Winkielman, 2012;
63 Pehlivanoglu et al., 2020; Shamay-Tsoory & Abu-Akel, 2016). As these effects can be of particular
64 interest for facial emotion processing, many behavioral studies have sought to elucidate how OXT
65 affects this ability. Despite the overall notion of OXT enhancing emotion recognition, closer inspection
66 of the findings reveals rather weak and inconsistent results, demonstrating OXT's variable nature and

67 the modulating impact of contextual and person-specific characteristics (for reviews and a meta-
68 analysis, see Bartz et al., 2011; Evans et al., 2014; Leppanen et al., 2017; Shahrestani et al., 2013; Van
69 IJzendoorn & Bakermans-Kranenburg, 2012). For example, whereas some studies found an overall
70 improvement of facial emotion recognition, irrespective of the valence of the expressions (Guastella et
71 al., 2010; Lischke et al., 2012), others have reported an OXT effect for positive (Di Simplicio et al., 2009;
72 Schulze et al., 2011) or negative (Fischer-Shofty et al., 2010) emotions only. In a similar vein, OXT has
73 been found to modulate approach-avoidance motivational tendencies, by enhancing sensitivity for
74 emotional stimuli that elicit approach-related behavior (Kemp & Guastella, 2011) and attenuating
75 sensitivity for negative emotional stimuli (Ellenbogen, 2018) that may elicit social withdrawal (Kemp &
76 Guastella, 2011). Likewise, exogenous OXT administration has been found to increase the perceived
77 salience of social cues in a context-specific manner (Shamay-Tsoory & Abu-Akel, 2016). For instance, in
78 addition to the enhanced prosocial behavior often encountered in positive and cooperative contexts,
79 increased negative emotions and behavior have also been reported after OXT administration in
80 competitive and aggressive contexts (Shamay-Tsoory et al., 2009). Furthermore, some studies showed
81 that the OXT induced improvement depends on task difficulty (Guastella et al., 2010) and on individual
82 characteristics, with more robust effects being observed in those individuals who initially (i.e. before
83 OXT treatment) scored poorer in terms of social-cognitive competence (Bartz et al., 2010) or displayed
84 lower levels of happiness when watching images of neutral faces (Pavarini et al., 2019). Indeed, in
85 addition to regulating the saliency of social cues or modulating the motivational tendencies, OXT has
86 also been found to enhance spontaneous facial mimicry in neurotypical adults (Korb et al., 2016;
87 Pavarini et al., 2019). This enhanced facial mimicry might in turn improve emotion recognition based on
88 sensorimotor simulation of the perceived expression in the brain (Wood et al., 2016), as a neural
89 feedback process elicits the corresponding emotion in the observer, supporting the perceptual
90 recognition of this perceived expression (Hess & Fischer, 2014; McIntosh, 1996).

91 Effects of a single dose of OXT on emotion recognition have also been investigated at the neural level,
92 mostly using functional magnetic resonance imaging (fMRI). In general, these studies showed

93 attenuated amygdala activity, mostly in response to negative social stimuli (for meta-analyses, see Grace
94 et al., 2018; Wang et al., 2017), which is considered to reflect a reduction in social anxiety. Yet, similar
95 to the behavioral data, results vary. For example, while attenuated amygdala activity has been reported
96 during implicit and explicit processing of both positive (Domes et al., 2007) and negative (Domes et al.,
97 2007; Gamer et al., 2010) emotions, enhanced amygdala activity for happy faces has also been reported
98 (Gamer et al., 2010). Furthermore, in women, a single dose of OXT enhanced activity in different brain
99 regions in relation to specific facial emotions (Domes et al., 2010): increased activation for angry faces
100 was reported in the inferior frontal gyrus and ventro-lateral prefrontal regions, for happy faces in the
101 inferior frontal gyrus and the fusiform gyrus, and for fearful faces in the medial and superior temporal
102 cortex and the bilateral fusiform gyrus. In addition, OXT also augmented functional connectivity
103 between the amygdala and the reward system (Wang et al., 2017) or the salience network (Grace et al.,
104 2018; Wang et al., 2017). Moreover, a recent meta-analysis proposed increased activity in the superior
105 temporal gyrus resulting from OXT administration as the main factor for improved emotion recognition
106 (Grace et al., 2018).

107 To date, few studies have investigated the effects of a single dose of OXT on facial emotion processing
108 using electroencephalography (EEG) (for a review, see Pehlivanoglu et al., 2020). Event-related potential
109 (ERP) studies investigating the modulatory effect of OXT reported shorter latencies of the N170
110 component (Tillman et al., 2019), as well as increased amplitudes of the N170 (Peltola et al., 2018) and
111 the vertex positive potential (VPP; Huffmeijer et al., 2013), indicating enhanced sensitivity and improved
112 neural efficiency to process emotional faces. Yet, results were inconsistent for the late positive potential
113 (LPP): some studies reported OXT-induced increases in LPP amplitudes (Huffmeijer et al., 2013),
114 whereas others reported no effects of OXT on this component (Peltola et al., 2018). Possibly, differences
115 in task demands, or differently chosen time windows to capture the ERP components might account for
116 the contrasting findings across studies, as selecting specific time windows to accurately measure the
117 ERP component(s) of interest is one of the most challenging aspects of classic ERP studies (Kappenman

118 & Luck, 2016). In addition, the low signal-to-noise ratio (SNR) of ERP measurements requires many trials,
119 resulting in long EEG recordings.

120 Given the challenges and limitations of classic ERP research, here, we applied a relatively novel but
121 highly sensitive EEG approach to investigate the modulatory effect of a single dose of OXT on facial
122 emotion processing: frequency-tagging EEG in combination with fast periodic visual stimulation.
123 Frequency-tagging EEG relies on the principle that brain activity synchronizes to a periodically flickering
124 stimulus (Adrian & Matthews, 1934) and elicits a brain response at exactly the same frequency of
125 stimulation (Norcia et al., 2015). This technique allows to reliably pinpoint individual differences in
126 sensitivity for various socio-communicative cues, such as faces versus non-social cues or facial
127 expressions and identities in infants (de Heering & Rossion, 2015), children (Van der Donck et al., 2019;
128 Vettori, Dzhelyova, et al., 2020; Vettori, Van der Donck, et al., 2020) and adults (Leleu et al., 2019;
129 Poncet et al., 2019). Accordingly, frequency-tagging EEG has demonstrated to differentiate robustly
130 between control populations and clinical populations that are characterized by social impairments, such
131 as children with autism spectrum disorder (Van der Donck et al., 2019; Vettori, Dzhelyova, et al., 2020;
132 Vettori, Van der Donck, et al., 2020) and adults with 22q11 deletion syndrome (Leleu et al., 2019).

133 Similar to previous studies (Dzhelyova et al., 2017; Van der Donck et al., 2020), we applied frequency-
134 tagging EEG with a facial expression oddball paradigm. In particular, neutral faces were periodically
135 presented in a rapid stream at 6 Hz (i.e. base rate) and were periodically interleaved with emotional
136 faces every fifth stimulus (i.e. at 1.2 Hz oddball rate). The neutral faces act as forward and backward
137 masks for the emotional faces, allowing us to selectively isolate the sensitivity to the expressions by
138 putting the emotional face processing system under tight temporal constraints (i.e. discarding
139 influences of mechanisms other than fast and automatic emotion extraction). The periodic presentation
140 at predefined, yet, different, frequency rates generates distinguishable frequency tags for the base and
141 oddball stimuli, allowing direct quantification of the neural responses, indicating the discrimination of
142 expressive faces amongst neutral faces. This makes frequency-tagging EEG a highly objective measure.

143 In addition, the rapid presentation enables a fast acquisition of many neural responses indexing
144 expression discrimination in only a few minutes of recording, with a high SNR. Previous research showed
145 that frequency-tagging oddball paradigms have a high test-retest reliability (Dzhelyova et al., 2019) and
146 are able to sensitively pinpoint differences in facial expression processing (Van der Donck et al., 2019,
147 2020), making them highly suited to monitor subtle changes in facial expression sensitivity, as for
148 example induced by intranasal OXT administration.

149 Accordingly, in the present study, we investigated the effect of a single dose of OXT on the neural
150 sensitivity to brief changes in facial expression. In separate trials, we included angry, fearful, and happy
151 faces as oddball stimuli in rapidly presented streams of neutral faces, in order to monitor possible
152 modulatory effects on both positive and negative facial expressions. To prevent expression
153 discrimination based on low-level visual features, we continuously changed the identity of the faces (i.e.
154 every image). Thirty-one healthy adult men participated in a double-blind, placebo-controlled, cross-
155 over trial, where they randomly received either a single dose of OXT or placebo during test sessions with
156 a two-week interval. In addition to the EEG measures, we administered a behavioral facial expression
157 matching task.

158 Following the social salience hypothesis (Shamay-Tsoory & Abu-Akel, 2016), we might expect to find an
159 overall salience effect of OXT, reflected in enhanced neural responses to facial expressions in general,
160 irrespective of emotion. However, in line with the inconsistencies in the OXT literature (Bartz et al.,
161 2011; Evans et al., 2014; Shahrestani et al., 2013), we anticipate a potential modulation of the OXT
162 treatment response depending on the expression valence. Specifically, and in line with evidence (Domes
163 et al., 2013; Ellenbogen, 2018; Xu et al., 2015) supporting the social approach/withdrawal hypothesis
164 (Kemp & Guastella, 2011), we expect OXT to selectively attenuate the neural response for negative facial
165 stimuli and enhance the neural sensitivity for positive facial stimuli.

166 2. Method

167 2.1. Participants

168 Thirty-one healthy right-handed male participants, aged between 18 and 32 years (mean age = 22.81
169 years, SD = 2.38 years), were included in this study. Only male participants were recruited in order to
170 avoid possible gender-dependent differences in response to OXT administration (Domes et al., 2010;
171 MacDonald, 2012) and in facial emotion processing (Kret & De Gelder, 2012). In addition to gender, age
172 (18-35 years old) and right-handedness, inclusion criteria further comprised the absence of any
173 diagnosed psychiatric, neurological or genetic disorders in the participant or a first-degree relative. All
174 participants had normal or corrected to normal vision. One participant reported color blindness, but as
175 he had no difficulties detecting the color changes of the fixation cross, he was not excluded.

176 The Medical Ethical Committee of the university hospital approved this study. Written informed consent
177 according to the Declaration of Helsinki was obtained from the participants. Participants received a
178 monetary compensation for their participation. The trial was registered with the ClinicalTrials.gov
179 database of the U.S. National Institutes of Health (NCT03096249).

180 2.2. Study design

181 We performed a randomized, double-blind, within-subjects, cross-over, placebo (PL)-controlled study,
182 with the sessions two weeks apart. More specifically, the experiment consisted of two identical test
183 sessions – except for the nasal spray the participants received – that took place at exactly the same time
184 of the day, 14 days apart. Based on random assignment, half of the participants received the OXT spray
185 (Syntocinon®, Sigma Tau) in the first session and the PL spray (saline solution of sodium chloride in
186 water) in the second session. For the other half of the participants, the order was reversed.

187 2.3. OXT administration

188 At the start of each session, participants received clear instructions on how to administer the nasal spray
189 themselves (Guastella et al., 2013), applying the widely used single dose of 24 international units (IU;
190 Guastella & MacLeod, 2012; Quintana et al., 2021) of OXT via three puffs of 4 IU per nostril. Based on
191 previous studies investigating the time interval between the intranasal administration of a single dose
192 of OXT and increased peripheral OXT levels (Daughters et al., 2015; Striepens et al., 2013), generally, a
193 30-45 minute wait-time is implemented post-administration (Guastella & MacLeod, 2012).
194 Consequently, in order to test during peak OXT concentrations, we incorporated an interval of 30
195 minutes between nasal spray administration and the start of the EEG paradigm. Potential side effects
196 or adverse events due to the OXT administration were monitored throughout the entire session (see
197 Supplementary Table 1).

198 2.4. Procedure

199 Participants were seated in a dimly lit room at 80 cm viewing distance of an LCD 24-in. computer screen,
200 placed at eye level, on which pictures of facial expressions were presented while recording EEG. During
201 the stimulus presentation, an orthogonal task was implemented to guarantee attentiveness of the
202 participants. A fixation cross, presented on the nasion of the presented faces, briefly (300 ms) changed
203 color from black to red 10 times within every sequence. The participants had to respond as soon and
204 accurately as possible when noticing the color changes. Note that the current study was part of a larger
205 project examining the effect of OXT on neural sensitivity for different subtle socio-emotional cues.

206 2.4.1 FPVS-EEG paradigm

207 The design was similar to previous studies (Dzhelyova et al., 2017; Van der Donck et al., 2020). Neutral
208 faces from continuously changing identities (i.e., every image) were displayed through sinusoidal
209 contrast modulation (0%–100%) at a 6 Hz base rate, periodically interleaved with an oddball stimulus
210 displaying an expression every fifth image (6 Hz/5 = 1.2 Hz oddball rate). Each sequence started with a

211 blank screen for a variable duration of 2–5 s. After two seconds of gradually fading in (0%–100%), the
212 images were presented for 60 s, followed by two seconds of gradually fading out (100%–0%). Three
213 conditions were included (i.e., the emotional expressions happiness, anger and fear), and each was
214 presented in a separate sequence and repeated four times, resulting in 12 sequences that were all
215 presented in a randomized order (Fig 1). The facial stimuli varied randomly in size between 80% and
216 120% of the original size.

217 **[Insert Fig.1 about here]**

218 2.4.2 Stimuli

219 The stimuli comprised full-front, full-color images of 14 individuals (seven females, seven males) from
220 the Karolinska Directed Emotional Faces database (Lundqvist et al., 1998), displaying either a neutral,
221 happy, angry or fearful expression. Mean pixel contrast and luminance of the pictures were equalized.
222 The images were set to a size of 300 x 450 pixels, equalizing corresponding to 5.08° x 6.58° of visual
223 angle, and were placed against a grey background.

224 2.4.3 EEG acquisition

225 We recorded EEG activity using a BIOSEMI Active-Two amplifier system with 64 Ag/AgCl electrodes and
226 two additional electrodes as reference and ground electrodes (Common Mode Sense active electrode
227 and Driven Right Leg passive electrode). Vertical eye movements were recorded via one electrode above
228 and one below the right eye. One electrode was placed at the corner of both eyes to record horizontal
229 eye movements. We recorded EEG and electrooculogram at 512 Hz.

230 2.4.4 EEG analysis

231 **Pre-processing.** Pre-processing was performed using ‘Letswave6’ (<http://www.nocions.org/letswave/>),
232 a toolbox running in Matlab 2017b (Mathworks). The continuous EEG data were cropped into segments
233 of 70 seconds (4 s before and 6 s after stimulus presentation). We applied a bandpass Butterworth filter
234 (fourth order; 0.1-100 Hz) and resampled the data to 256 Hz. We applied independent component

235 analysis via the runica algorithm (Makeig et al., 1995) for two participants who blinked on average more
236 than 2SD above the mean (average number of blinks per second across participants = 0.10, SD = 0.09)
237 and we removed the component that accounted for most of the variance. Noisy or artefact-ridden
238 channels were re-estimated via linear interpolation using the three spatially nearest, neighboring
239 electrodes (not more than 5% of the electrodes (i.e. three electrodes) were interpolated). All data
240 segments were re-referenced to a common average reference.

241 **Frequency domain analysis.** The pre-processed data segments were then cropped to contain an integer
242 number of 1.2 Hz cycles beginning immediately after the fade-in until approximately 59.22 seconds (72
243 cycles). After averaging the data in the time domain per condition and for each participant separately,
244 we applied a fast Fourier transformation (FFT), yielding amplitude spectra with a spectral resolution of
245 0.017 Hz. To obtain a measure of neural sensitivity for facial expressions (Dzhelyova et al., 2017), we
246 calculated baseline-subtracted amplitudes at the oddball frequency and its harmonics (i.e., $n \cdot F/5 = 2.4$
247 Hz, 3.6 Hz, etc.), by subtracting the average amplitude level of the 20 surrounding bins from the
248 amplitude of the frequency bin of interest (Retter & Rossion, 2016). These 20 surrounding bins are the
249 10 bins on each side of the target frequency bin, excluding the immediately neighboring bins and the
250 two bins with the most extreme values. Baseline-subtracted amplitudes express responses in
251 amplitudes (μV) that can be summed across significant harmonics to quantify the overall base and
252 oddball response (Retter & Rossion, 2016). In addition, we calculated signal-to-noise ratio (SNR; by
253 dividing the amplitude value of the target frequency bin by the average amplitude of the 20 surrounding
254 frequency bins) for visualization, as this allows to visualize even small response amplitudes with high
255 SNR (Rossion et al., 2012).

256 In order to assess the significance of the responses to define the number of base and oddball harmonics
257 to include in the analyses, Z-scores were calculated using the mean and standard deviation of the 20
258 frequency bins surrounding the bin of interest (Liu-Shuang et al., 2014). Harmonics were considered
259 significant until the Z-score no longer exceeded 1.64 ($p < .05$), for two consecutive harmonics.

260 Consequently, we quantified the oddball response as the sum of the responses of the first seven
261 harmonics (i.e. until $7F/5 = 8.4$ Hz), excluding the 6 Hz general response. The base rate response (i.e. 6
262 Hz) was quantified as the summed responses of the base rate and its following two harmonics (2F and
263 $3F = 12$ Hz and 18 Hz, respectively).

264 Additional analyses were performed at the individual subject level by averaging the raw FFT spectrum
265 per ROI and cropping it into segments centered at the oddball frequency and its harmonics, surrounded
266 by 20 neighboring bins on each side that represent the noise level. Similar to previous studies (Van der
267 Donck et al., 2019, 2020), these spectra were summed across the significant harmonics and transformed
268 into an individual Z-score for each condition and for all ROIs.

269 **Defining regions of interest (ROIs).** Previous research using similar frequency-tagging facial expression
270 processing EEG paradigms (Dzhelyova et al., 2017; Van der Donck et al., 2019, 2020) has consistently
271 identified three regions to be the most responsive for emotion discrimination as assessed by oddball
272 stimulation. Likewise, also in the present study, the highest oddball responses – capturing all relevant
273 oddball activity – were measured over these left and right occipito-temporal (LOT and ROT region) and
274 medial-occipital (MO region) sites. Accordingly, region-of-interest (ROI) analyses were performed to
275 examine OXT-treatment effects within these regions by averaging the summed baseline-subtracted
276 oddball responses over channels P7, P9, and PO7 for the LOT region, over channels P8, P10, and PO8
277 for the ROT region and over channels Iz and Oz for the MO region (see Fig 2).

278 While the 1.2 Hz oddball response reflects the strength of neural expression discrimination, the 6 Hz
279 base rate response reflects the contrast between the facial stimuli and the background (Dzhelyova et
280 al., 2017). As this general stimulation response is mainly driven by low-level visual features, it is typically
281 characterized by a medial-occipital topography (Dzhelyova & Rössion, 2014a). ~~As this general visual~~
282 ~~stimulation response is not the focus of this intervention study, we report the results on this base rate~~
283 ~~response in Supplementary Fig 1.~~

284 2.5. Behavioral facial expression processing

285 In order to investigate whether potential prosocial OXT effects at the neural level would also be
286 reflected at the behavioral level, we additionally administered the Emotion-matching task (Palermo et
287 al., 2013) subsequently to the EEG paradigm. This is a computerized facial expression processing task
288 where three faces are shown simultaneously on the screen, and participants have to detect a target
289 face showing a different facial emotion compared to two distractor faces both showing the same
290 expression. All faces display one of the six basic emotions. Participants were instructed to select the
291 target face by pressing the corresponding number (i.e. 1, 2 or 3) on the keyboard. To ensure that all
292 data was gathered within the assumed 75-minutes window of boosted levels of peripheral OXT
293 (Daughters et al., 2015; Striepens et al., 2013), we used the shorter 65-item version of the task,
294 preceded by four practice trials (for specifics, see Palermo et al., 2013).

295 2.6. Statistical analyses

296 We performed linear mixed models (LMM; 'Afex' package version 0.28-1 in R version 4.0.5 (Singmann
297 et al., 2020)) to assess the modulatory effects of facial expressions and treatment on the participants'
298 **EEG baseline-subtracted amplitudes** recorded over the LOT, ROT and MO regions, with *ROI* (LOT, ROT,
299 MO), *emotion* (anger, fear, happiness), and *treatment condition* (OXT, PL) as fixed effects. Since half of
300 the participants received OXT during their first session, while the other half started with the PL
301 condition, session order was added as nuisance covariate to adjust for its effect on the neural responses.
302 We included a random intercept and random slope for each of the fixed factors per participant. Nine
303 outlying data points were detected using the median absolute deviation and removed. Considering the
304 previously reported modulatory effect of expression valence on the OXT treatment response (Evans et
305 al., 2014), additional LMMs were performed for each of the three facial expressions (anger, fear and
306 happiness) separately. Tukey-corrected post-hoc T-tests were performed on the fitted models for all
307 significant effects ('emmeans' package version 1.6.0 (Lenth et al., 2019)). Cohen's d effect sizes were
308 calculated by dividing the least square means difference by the pooled standard deviation.

309 In keeping with the previous analyses, we also performed LMMs on the **behavioral measures** of the
310 orthogonal fixation cross color chance detection task and the Emotion-matching task, which had no
311 outlying data points. For the orthogonal task, fixed factors were *emotion* (anger, fear, happiness) and
312 *treatment condition* (OXT, PL). For the Emotion-matching task, the LMM only included *treatment*
313 *condition* as fixed factor. For all behavioral measures, session order was added as a nuisance covariate
314 as well. Tukey-corrected post-hoc T-tests were performed for all significant effects.

315 When the LMMs did not display any treatment effect, Bayes Factors (BFs) were computed to estimate
316 the statistical evidence in favor of the null hypothesis ('BayesFactor' package version 0.9.12-4.2 in R;
317 Morey et al., 2018). By computing the BFs, we compared the fitting of two competing models: the model
318 as described in the LMMs versus the same model without the factor "treatment condition". In line with
319 the heuristic classification scheme of Lee and Wagenmakers (2013), BF-values lower than 1 indicate
320 support for the null hypothesis, whereas values higher than 1 indicate support for the alternative
321 hypothesis. Yet, in general, BF-values in between 3 and 1/3 indicate that the data are ambiguous, making
322 the outcome indecisive. Additionally, we calculated the mean posterior difference between the two
323 treatment conditions for all emotions, as well as their 95% highest density interval (HDI).

324 ~~Since half of the participants received OXT during their first session, while the other half started with~~
325 ~~the PL condition, we performed secondary analyses accounting for potential effects of 'session order',~~
326 ~~by adding this factor as a nuisance covariate in all the performed analyses. Overall, the pattern of results~~
327 ~~was qualitatively similar to the main analyses, confirming no modulatory effect of the factor 'session~~
328 ~~order' on the reported effects.~~

329 4.3. Results

330 4.1.3.1. Reported side effects

331 Participants were monitored for potential side effects until three hours after the single-dose
332 administration. As can be observed in Supplementary Table 1, side effects were only minimal, non-

333 treatment specific (cf. insignificant Pearson Chi-square tests), and were possibly due to EEG
334 administration with a tight head cap and fixating on a screen for a prolonged period (e.g. headache
335 reported in 7 OXT and 8 PL participants).

336 4.2.3.2. Neural responses

337 All three expressions elicited clear expression-discrimination EEG responses at the oddball frequency
338 and its harmonics (Fig 2), mostly centered over lateral occipito-temporal sites (Fig 3).

339 [Insert Fig.2 about here]

340 4.2.13.2.1 Estimated reliability and power analysis

341 A power analysis was performed to calculate the power to detect true differences. The highly reliable
342 measurements (with between-session correlations of $r = .57$, $r = .70$ and $r = .74$ for anger, fear and
343 happiness, respectively; all $p < 0.001$) included in this repeated-measures design substantially enhanced
344 the power of this study. Based on the average correlation ($r = .67$), a power analysis with G*Power 3
345 (Faul et al., 2007) revealed a power of .91 to detect group differences, even for a small effect size (0.25),
346 indicating that our study design yielded adequate power.

347 4.2.23.2.2 Expression discrimination responses

348 The main analysis across all three facial expressions revealed no main effect of treatment ($F(1,30.15) =$
349 0.72 , $p = 0.40$), nor emotion ($F(2,2928.99) = 2.110$, $p = 0.144$) or ROI ($F(2,28.758.99) = 1.7877$, $p = 0.199$).
350 Nor did we find a significant effect of sessions order ($F(1,28.94) = 0.05$, $p = 0.82$). The marginally
351 significant interaction effect between treatment condition and emotion ($F(2,349.9452.5) = 2.632$, $p =$
352 0.07), suggested an opposite effect of treatment for angry versus fearful and happy faces. However,
353 subsequent Tukey-corrected post-hoc t-tests failed to reveal any treatment effects for any of the
354 emotions ($M_{\text{anger OXT}} = 0.47 \mu\text{V}$, $M_{\text{anger PL}} = 0.50 \mu\text{V}$; $M_{\text{fear OXT}} = 0.54 \mu\text{V}$, $M_{\text{fear PL}} = 0.50 \mu\text{V}$; $M_{\text{happiness OXT}} = 0.61$
355 μV , $M_{\text{happiness PL}} = 0.54 \mu\text{V}$; $t(74.7)_{\text{anger OXT-PL}} = -0.73$, $d = 0.09$, 95% CI [-0.38 – 0.20]; $t(74.1)_{\text{fear OXT-PL}} = 1.28$,
356 $d = 0.13$, 95% CI [-0.16 – 0.42]; $t(74.8)_{\text{happiness OXT-PL}} = 1.46$, $d = 0.15$, 95% CI [-0.14 – 0.45]; all $p > 0.15$).

357 The significant emotion by ROI interaction ($F(4,35)_{13.4187} = 11.867, p < 0.001$) revealed higher neural
358 responses in the MO region for happy ($M = 0.65 \mu V$) versus angry ($M = 0.33 \mu V$) and fearful ($M = 0.46$
359 μV) faces ($t(65.9)_{\text{anger-happiness}} = -5.65, p < 0.001, d = -0.86, 95\% \text{ CI } [-1.23 - -0.49]$; $t(70.5)_{\text{fear-happiness}} = -3.44,$
360 $p = 0.003, d = -0.49, 95\% \text{ CI } [-0.85 - -0.13]$), and for fearful versus angry faces ($t(138.12) = -3.01, p =$
361 $0.009, d = -0.47, 95\% \text{ CI } [-0.83 - -0.11]$). In addition, for angry faces, the neural responses recorded over
362 the MO region were significantly lower than in the LOT ($M = 0.55 \mu V$; $t(57.2) = 3.45, p = 0.003, d = 0.68,$
363 $95\% \text{ CI } [0.32 - 1.04]$) and ROT ($M = 0.56 \mu V$; $t(55.85) = -4.01, p < 0.001, d = -0.70, 95\% \text{ CI } [-1.06 - -0.33]$)
364 regions. There were no other significant two- or three-way interaction effects (all $p > 0.32$).

365 The BF analysis provided decisive evidence for a lack of treatment effect: $BF = 0.000052$. When
366 comparing the neural responses in the OXT versus PL condition, we found a mean posterior decrease
367 for angry faces of $0.057 \mu V$ ($95\% \text{ HDI} = [-0.13 \ 0.01]$), and a mean posterior increase for fearful ($0.02 \mu V$;
368 $95\% \text{ HDI} = [-0.05 \ 0.09]$) and happy ($0.04 \mu V$; $95\% \text{ HDI} = [-0.03 \ 0.11]$) faces, all indicating that the
369 treatment effect is negligible.

370 [Insert Fig.3 about here]

371 In line with the approach-avoidance hypothesis and the marginally significant emotion by treatment
372 effect, we also calculated LMMs for each facial expression separately. Yet, also these additional LMMs
373 did not reveal any main effect of treatment ($F(1,8)_{78.5232} = 0.875, F(1,88.778.84)_{\text{Fear}} = 1.7782,$
374 $F(1,88)_{\text{Happiness}} = 2.59$; all $p > 0.11$), nor any treatment by ROI interaction ($F(2,8)_{78.5019} = 1.145,$
375 $F(2,88.88.7784)_{\text{Fear}} = 0.854, F(2,88)_{\text{Happiness}} = 0.09$; all $p > 0.32$). No significant effects of session order
376 were detected (all $p > 0.32$).

377 Statistical analysis of the individual subject data revealed that the majority of participants showed robust
378 individual expression discrimination responses (i.e. z-scores $> 1.64, p < 0.05$) in at least one of the three
379 ROIs, irrespective of treatment condition (see Supplementary Table 2).

380 [Insert Fig.3 about here]

381 4.2.33.2.3 General visual base rate responses

382 In line with previous reports, the LMM of the ~~the~~ general visual base rate response (i.e. 6 Hz) revealed
383 a significant yielded the highest responses in the MO region (main effect of ROI ($F(2,29.94) = 26.11$, $p < 0.001$),
384 $p < 0.001$) and a significant two-way interaction between emotion and ROI ($F(4,395.57) = 2.96$, $p = 0.02$).
385 As expected, we found the highest neural responses over the medial-occipital (MO) region for all three
386 emotions ($M_{\text{anger MO}} = 3.22 \mu\text{V}$; $M_{\text{fear MO}} = 3.32 \mu\text{V}$; $M_{\text{happiness MO}} = 3.28 \mu\text{V}$; $t(30.1)_{\text{anger LOT-MO}} = -6.85$, $d = -$
387 1.59 , 95% CI [-1.99 – -1.18]; $t(30.1)_{\text{anger MO-ROT}} = 4.80$, $d = 1.24$, 95% CI [0.85 – 1.62]; $t(30.1)_{\text{fear LOT-MO}} = -$
388 7.26 , $d = -1.67$, 95% CI [-2.07 – -1.25]; $t(30.1)_{\text{fear MO-ROT}} = 5.18$, $d = 1.35$, 95% CI [0.96 – 1.74]; $t(30.1)_{\text{happiness$
389 $\text{LOT-MO}} = -7.34$, $d = -1.69$, 95% CI [-2.10 – -1.28]; $t(30.1)_{\text{happiness MO-ROT}} = 5.38$, $d = 1.39$, 95% CI [1.00 – 1.79];
390 all $p < 0.001$). Responses in the right occipito-temporal (ROT) region ($M_{\text{anger}} = 1.97 \mu\text{V}$; $M_{\text{fear}} = 1.97 \mu\text{V}$;
391 $M_{\text{happiness}} = 1.90 \mu\text{V}$) were also significantly larger than in the left occipito-temporal (LOT) region (M_{anger}
392 $= 1.37 \mu\text{V}$; $M_{\text{fear}} = 1.35 \mu\text{V}$; $M_{\text{happiness}} = 1.25 \mu\text{V}$; $t(31.3)_{\text{anger}} = 2.64$, $p = 0.04$, $d = 0.53$, 95% CI [0.17 – 0.89];
393 $t(31.3)_{\text{fear}} = 2.67$, $p = 0.03$, $d = 0.56$, 95% CI [0.20 – 0.92]; $t(31.4)_{\text{happiness}} = 2.48$, $p = 0.04$, $d = 0.53$, 95% CI
394 [0.17 – 0.89]). NAs expected, no treatment effects nor any interactions with treatment were observed
395 for the general visual base rate response (for any of the three facial expressions (all $p > 0.153$, see
396 Supplementary Fig 41)).

397 As for the oddball analysis, also the BF analysis of the general visual response to faces revealed
398 conclusive evidence in favor of the null hypothesis: BF = 0.000028. For angry faces, across the three
399 ROIs, we found a negligible mean posterior decrease in neural responses in the OXT condition compared
400 to the PL condition ($0.12 \mu\text{V}$; 95% HDI = [-0.29 0.05]), and a negligible mean posterior increase for fearful
401 ($0.06 \mu\text{V}$; 95% HDI = [-0.11 0.24]) and happy ($0.06 \mu\text{V}$; 95% HDI = [-0.11 0.24]) faces.

402 [Insert Fig.4 about here]

403 4.3.3.3. Behavioral measures: Orthogonal task and explicit facial 404 emotion processing

405 Results of the LMM revealed equal performances during the PL and OXT sessions on the fixation cross
406 color change detection task, both in terms of accuracy ($M_{PL} = 95\%$, $SD_{PL} = 0.05$; $M_{OXT} = 95\%$, $SD_{OXT} = 0.06$;
407 $F(1,150) = 0.01$, $p = 0.94$, $d = 0.009$, 95% CI [-0.28 – 0.30]) and in terms of reaction times ($M_{PL} = 0.43$ s,
408 $SD_{PL} = 0.05$; $M_{OXT} = 0.43$ s, $SD_{OXT} = 0.04$; $F(1,150) = 0.26$, $p = 0.77$, $d = -0.13$, 95% CI [-0.42 – 0.16]). These
409 results indicate that the participants were equally attentive to the screen within each treatment session.

410 No other main or interaction effects were found (all $p > 0.27$).

411 BF analyses of the accuracies and reaction times showed moderate evidence for an absent treatment
412 effect: $BF_{ACC} = 0.042$ and $BF_{RT} = 0.080$. On average, participants were slightly better (mean posterior
413 difference = 0.00049; 95% HDI = [-0.011 0.012]) and slightly faster (mean posterior difference = -0.0051;
414 95% HDI = [-0.011 0.0009] in detecting the color change of the fixation cross during the OXT condition
415 versus the PL condition.

416 In addition, the LMM investigating the participants' performances on the Emotion-matching task also
417 revealed equal accuracy ($M_{PL} = 75\%$, $SD_{PL} = 0.07$; $M_{OXT} = 74\%$, $SD_{OXT} = 0.10$; $F(1,30) = 0.12$, $p = 0.73$, $d =$
418 0.06 , 95% CI [-0.44 – 0.55]) and equal reaction times ($M_{PL} = 4.11$ s, $SD_{PL} = 1.31$; $M_{OXT} = 4.03$ s, $SD_{OXT} =$
419 1.16 ; $F(1,30) = 0.72$, $p = 0.40$, $d = 0.07$, 95% CI [-0.42 – 0.57]). Hence, these results suggest that OXT
420 treatment does not have a modulatory effect on explicit facial expression processing, nor did the order
421 of the treatment conditions ($p_{acc} = 0.60$; $p_{rt} = 0.34$).

422 For the accuracies and reaction times on the Emotion-matching task, the BF analyses only provide
423 anecdotal evidence for the null hypothesis: $BF_{ACC} = 0.2739$ and $BF_{RT} = 0.3712$. We found a slightly
424 reduced emotion matching performance in the OXT condition (mean posterior difference = -0.0043;
425 95% HDI = [-0.030 0.022] compared to the PL condition, as well as a reduction in reaction times (mean
426 posterior difference = -75.59; 95% HDI = [-286.633 128.427]).

427 5.4. Discussion

428 In the current randomized, double-blind, cross-over, placebo-controlled study, we applied frequency-
429 tagging EEG to investigate the modulating effects of a single dose of OXT on the automatic and implicit
430 neural sensitivity of 31 healthy adult men to brief changes in facial expression.

431 We did not find an OXT treatment effect, neither at the neural level, nor on the behavioral task assessing
432 the accuracy and speed of matching emotional expressions.

433 Similar to previous research (Van der Donck et al., 2019, 2020), we showed that neural expression
434 discrimination is mainly driven by EEG responses in higher-level occipito-temporal regions, and that
435 expressions crucially involving the mouth area (i.e. happiness and fear) additionally recruit medial-
436 occipital perceptual regions. Similar to what has been demonstrated before with comparable frequency-
437 tagging EEG paradigms (Dzhelyova et al., 2019), the neural expression-discrimination responses
438 obtained in our study showed a high test-retest reliability. Together with the ability to sensitively identify
439 individuals characterized by socio-communicative impairments such as autism spectrum disorder (Van
440 der Donck et al., 2019, 2020) and 22q11.2 deletion syndrome (Leleu et al., 2019), in principle, these
441 combined characteristics of reliability and sensitivity would have made the frequency-tagging EEG
442 approach perfectly suited to monitor the impact of oxytocin treatment.

443 5.1.4.1. No general enhancement of emotional salience, nor any 444 modulation of social approach or withdrawal tendencies

445 In general, our findings argue against a strong account of the social salience hypothesis of OXT (Shamay-
446 Tsoory & Abu-Akel, 2016). This framework posits that OXT uniformly increases the salience of social
447 stimuli, irrespective of their valence. This was not the case in our study, as there was no generally
448 enhanced neural sensitivity to the three displayed emotions.

449 Neither do our findings align with the social approach/withdrawal hypothesis (Kemp & Guastella, 2011),
450 stating that OXT enhances social approach-related behavior and diminishes social withdrawal. At a
451 neural level, this would have been reflected in increased activation in response to positive facial
452 expressions and reduced responses when processing negative facial expressions. However, as the
453 oxytocinergic effects in response to positive and negative facial expressions are thought to be largely
454 independent of each other (Ellenbogen, 2018), we could have observed either one of these effects.

455 Although previous studies have reported modulatory OXT effects on the implicit processing of emotional
456 faces (e.g. presented for < 300 ms; Shahrestani et al., 2013), our EEG findings did not reveal such an
457 impact. Possibly, this absence of OXT-induced modulation of neural responses could be explained by
458 the fact that OXT might exert little effect when the emotional sensitivity is already high, as suggested by

459 ~~(Leknes and colleagues et al., (2013). Indeed, as OXT has been found to improve facial expression~~
460 ~~processing in particular in individuals for whom the task is more demanding (Bartz et al., 2011; Mierop~~
461 ~~et al., 2020), our implicit emotion processing paradigm might not have been fully suited to detect~~
462 ~~enhanced neural sensitivity in individuals who may already perform well in face processing at baseline.~~
463 ~~Moreover, while fMRI studies have demonstrated oxytocinergic effects in several (subcortical) brain~~
464 ~~areas, such as the amygdala (Grace et al., 2018; Wang et al., 2017), scalp EEG might not be optimal to~~
465 ~~detect these effects. Yet, if underlying brain areas might have been influenced by OXT, this might also~~
466 ~~have been reflected in improved behavioral emotion matching, which was neither the case in our study.~~
467 ~~If OXT would only affect the processing of facial expressions, this would have been reflected in~~
468 ~~selectively enhanced neural responses to the emotional stimuli, either for specific emotions or for all~~
469 ~~emotions. However, if OXT would enhance the saliency of social stimuli in general, the effect may not~~
470 ~~have been limited to emotional faces but may encompass any type of faces, thus also the neutral ones.~~
471 ~~This would imply also observing higher base rate responses in the OXT versus PL condition, as these~~
472 ~~reflect the processing of the facial stimuli, both neutral and expressive. Previous studies have indeed~~
473 ~~provided evidence for a modulatory OXT effect on face processing in general (Andari et al., 2016; Hovey~~

474 et al., 2020). In adults with autism, for example, OXT has been shown to enhance neural activity in
475 bilateral occipito-temporal regions during the processing of neutral facial stimuli (Andari et al., 2016).
476 Yet, for the participants included in our sample, this was not the case as the general neural response to
477 faces was not modulated by OXT, not in the occipito-temporal regions, nor in the MO region. Some
478 studies suggest that the modulatory effect of OXT on face processing may rather be attributed to
479 enhanced face memory -as OXT increases the familiarity of previously encountered faces- instead of
480 enhanced facial perception (for a review, see Lopatina et al., 2018; Rimmele et al., 2009). In our study,
481 the rapid presentation rate only allows a single glance at the images, which are all preceded and
482 followed by forward and backward masks, thereby interfering with conscious processing. However,
483 even if OXT would have enhanced the recognition of the facial stimulus as a ‘known/familiar’ stimulus -
484 even at this presentation rate-, we would rather expect reduced neural responses in the OXT condition
485 due to the larger adaptation effects for familiar stimuli.

486 To ensure that we did not overlook a possible OXT treatment effect in the latency of the responses -
487 which we would not detect within the frequency-domain- we also performed a time-domain analysis of
488 the waveforms time-locked to the oddball stimuli (i.e. expressive faces; see Supplementary Materials
489 for method and results). Similar to previous studies investigating facial expression processing at the
490 neural level (DaSilva et al., 2016; Dzhelyova et al., 2017), our data yielded a clear tri-phasic response to
491 brief changes in facial expressions. This tri-phasic response consisted of three differential components
492 (P1, N1 and P2), rather than ERP components, as these components already reflect the contrast
493 between the neutral faces and the expressive faces (Dzhelyova & Rossion, 2014b). One might argue that
494 the time-locked waveforms elicited by these facial expressions may overlap with the tri-phasic OXT-
495 related ERP modulation, as proposed by Pehlivanoglu and colleagues (2020). According to these
496 authors, the ERP modulation effect of OXT starts in the perception stage (100-200 ms), where it
497 enhances the perceived salience of stimuli. Second, during the selection stage (200-300 ms), OXT is
498 thought to facilitate attention towards social stimuli, and, third, during the evaluation stage (>300 ms),
499 the OXT-induced increased sustained attention to motivationally salient information converts to higher-

500 order cognitive processing (Pehlivanoglu et al., 2020). While the time-windows defined in our study may
501 map perfectly on these postulated latency-dependent OXT modulatory stages, the selection of our time-
502 windows was based on the average waveform of OXT and PL combined. Importantly, in terms of
503 latencies and amplitudes, our results clearly show an identical tri-phasic response in the PL condition as
504 in the OXT condition, thereby refuting the idea of an OXT-specific modulation of the signal. If OXT would
505 indeed have reduced the time required for facial (emotion) processing, we could have expected to find
506 a shorter latency for the expression discrimination responses in the OXT versus the PL condition.
507 However, no significant OXT effects were discovered in the time-domain, neither in the latency of the
508 components, nor in their amplitudes.

509

510 5.3.4.2. No modulation of behavioral emotion matching

511 performance in healthy individuals

512 In addition, we found no improvement of behavioral facial emotion processing after OXT administration.
513 Although OXT has mostly been reported to improve the accuracy of emotion recognition, it might also
514 reduce the time that is required to process the faces in order to recognize emotions, without
515 compromising the accuracy (Hubble et al., 2017). Yet, in our study, both the accuracy and reaction times
516 of the behavioral emotion processing performances seem to be unaffected by a single dose of OXT.
517 However, it should be noted that the participants included in our study were healthy adults with
518 adequate baseline emotion processing abilities (Palermo et al., 2013; behavioral results). Accordingly,
519 the possibility cannot be ruled out that the lack of OXT treatment effects on the behavioral emotion
520 processing task might reflect ceiling performance, allowing no further behavioral improvement (Bartz
521 et al., 2011; Guastella et al., 2010).

522 In addition, the absence of behavioral OXT effects could possibly be attributed to the task we used in
523 this study. Possibly, OXT-induced enhanced emotion processing depends more on higher-level

524 processes associated with labeling and recognizing facial expressions, rather than comparing (matching)
525 emotional faces, given that (Horta de Macedo and colleagues et al., (2014) ~~neither also did not find~~
526 improved emotion matching performance in healthy adult participants after intranasal OXT
527 administration.

528 One might argue that the relatively small sample size (N = 31) yields relatively low statistical power to
529 detect main effects of intranasally administered OXT (Mierop et al., 2020). It is to say, the non-significant
530 p-values may either indicate data insensitivity due to a small sample size or they may reflect actual null
531 results (Winterton et al., 2021). Yet, investigating the evidence in favor of the null hypothesis via Bayes
532 Factors, convincingly confirms the absence of an OXT effect on neural and behavioral facial expression
533 processing.

534 To conclude, we applied frequency-tagging EEG to investigate the effects of a single dose of OXT on the
535 automatic and implicit neural sensitivity for positive and negative facial expressions. Yet, our findings
536 from the frequency- and time-domain showed that OXT did not influence the sensitivity to (specific)
537 facial expressions, nor did it affect the timing of these neural processes. More specifically, our results
538 did not demonstrate enhanced emotional salience, nor did the results reflect a modulatory effect of
539 OXT on social approach-avoidance tendencies. —These OXT-induced effects were absent both on the
540 neural and the behavioral level, possibly due to ceiling emotional face processing performances.

541

542

543 References

- 544 Adrian, E. D., & Matthews, B. H. C. (1934). The Berger Rhythm: Potential changes from the occipital
545 lobes in man. *Brain*, *57*, 355–385.
- 546 Andari, E., Richard, N., Leboyer, M., & Sirigu, A. (2016). Adaptive coding of the value of social cues with
547 oxytocin, an fMRI study in autism spectrum disorder. *Cortex*, *76*, 79–88.
548 <https://doi.org/10.1016/j.cortex.2015.12.010>
- 549 Bartz, J. A., Zaki, J., Bolger, N., Hollander, E., Ludwig, N. N., Kolevzon, A., & Ochsner, K. N. (2010). Oxytocin
550 Selectively Improves Empathic Accuracy. *Psychological Science*, *21*(10), 1426–1428.
551 <https://doi.org/10.1177/0956797610383439>
- 552 Bartz, J. A., Zaki, J., Bolger, N., & Ochsner, K. N. (2011). Social effects of oxytocin in humans: Context and
553 person matter. *Trends in Cognitive Sciences*, *15*(7), 301–309.
554 <https://doi.org/10.1016/j.tics.2011.05.002>
- 555 Churchland, P. S., & Winkielman, P. (2012). Modulating social behavior with oxytocin: How does it work?
556 What does it mean? *Hormones and Behavior*, *61*(3), 392–399.
557 <https://doi.org/10.1016/j.yhbeh.2011.12.003>
- 558 DaSilva, E. B., Crager, K., Geisler, D., Newbern, P., Orem, B., & Puce, A. (2016). Something to sink your
559 teeth into: The presence of teeth augments ERPs to mouth expressions. *NeuroImage*, *127*, 227–
560 241. <https://doi.org/10.1016/j.neuroimage.2015.12.020>
- 561 Daughters, K., Manstead, A. S. R., Hubble, K., Rees, A., Thapar, A., & van Goozen, S. H. M. (2015). Salivary
562 Oxytocin Concentrations in Males following Intranasal Administration of Oxytocin: A Double-Blind,
563 Cross-Over Study. *PLOS ONE*, *10*(12), e0145104. <https://doi.org/10.1371/journal.pone.0145104>
- 564 de Heering, A., & Rossion, B. (2015). Rapid categorization of natural face images in the infant right
565 hemisphere. *eLife*, *4*, 1–14. <https://doi.org/10.7554/eLife.06564>
- 566 Di Simplicio, M., Massey-Chase, R., Cowen, P. J., & Harmer, C. J. (2009). Oxytocin enhances processing
567 of positive versus negative emotional information in healthy male volunteers. *Journal of*
568 *Psychopharmacology*, *23*(3), 241–248. <https://doi.org/10.1177/0269881108095705>
- 569 Domes, G., Heinrichs, M., Gläscher, J., Büchel, C., Braus, D. F., & Herpertz, S. C. (2007). Oxytocin
570 Attenuates Amygdala Responses to Emotional Faces Regardless of Valence. *Biological Psychiatry*,
571 *62*(10), 1187–1190. <https://doi.org/10.1016/j.biopsych.2007.03.025>

572 Domes, G., Lischke, A., Berger, C., Grossmann, A., Hauenstein, K., Heinrichs, M., & Herpertz, S. C. (2010).
573 Effects of intranasal oxytocin on emotional face processing in women. *Psychoneuroendocrinology*,
574 35(1), 83–93. <https://doi.org/10.1016/j.psyneuen.2009.06.016>

575 Domes, G., Sibold, M., Schulze, L., Lischke, A., Herpertz, S. C., & Heinrichs, M. (2013). Intranasal oxytocin
576 increases covert attention to positive social cues. *Psychological Medicine*, 43(8), 1747–1753.
577 <https://doi.org/10.1017/S0033291712002565>

578 Dzhelyova, M., Jacques, C., Dormal, G., Michel, C., Schiltz, C., & Rossion, B. (2019). High test-retest
579 reliability of a neural index of rapid automatic discrimination of unfamiliar individual faces. *Visual*
580 *Cognition*, 27(2), 127–141. <https://doi.org/10.1080/13506285.2019.1616639>

581 Dzhelyova, M., Jacques, C., & Rossion, B. (2017). At a single glance: Fast periodic visual stimulation
582 uncovers the spatio-temporal dynamics of brief facial expression changes in the human brain.
583 *Cerebral Cortex*, 1–18. <https://doi.org/10.1093/cercor/bhw223>

584 Dzhelyova, M., & Rossion, B. (2014a). Supra-additive contribution of shape and surface information to
585 individual face discrimination as revealed by fast periodic visual stimulation. *Journal of Vision*,
586 14(15), 1–14. <https://doi.org/10.1167/14.14.15>

587 Dzhelyova, M., & Rossion, B. (2014b). The effect of parametric stimulus size variation on individual face
588 discrimination indexed by fast periodic visual stimulation. *BMC Neuroscience*, 15(87).
589 <https://doi.org/10.1186/1471-2202-15-87>

590 Elfenbein, H. A., & Ambady, N. (2002). On the universality and cultural specificity of emotion recognition:
591 A meta-analysis. *Psychological Bulletin*, 128(2), 203–235. [https://doi.org/10.1037/0033-](https://doi.org/10.1037/0033-2909.128.2.203)
592 2909.128.2.203

593 Ellenbogen, M. A. (2018). Oxytocin and Facial Emotion Recognition. In R. Hurlemann & V. Grinevich
594 (Eds.), *Behavioral Pharmacology of Neuropeptides: Oxytocin* (pp. 349–374). Springer International
595 Publishing. <https://doi.org/10.1007/978-1-4419-7931-5>

596 Evans, S. L., Dal Monte, O., Noble, P., & Averbeck, B. B. (2014). Intranasal oxytocin effects on social
597 cognition: A critique. *Brain Research*, 1580, 69–77.
598 <https://doi.org/10.1016/j.brainres.2013.11.008>

599 Faul, F., Erdfelder, E., Lang, A. G., & Buchner, A. (2007). G*Power 3: A flexible statistical power analysis
600 program for the social, behavioral, and biomedical sciences. *Behavior Research Methods*, 39(2),
601 175–191. <https://doi.org/10.3758/BF03193146>

602 Fischer-Shofty, M., Shamay-Tsoory, S. G., Harari, H., & Levkovitz, Y. (2010). The effect of intranasal

603 administration of oxytocin on fear recognition. *Neuropsychologia*, 48(1), 179–184.
604 <https://doi.org/10.1016/j.neuropsychologia.2009.09.003>

605 Gamer, M., Zurowski, B., & Büchel, C. (2010). Different amygdala subregions mediate valence-related
606 and attentional effects of oxytocin in humans. *Proceedings of the National Academy of Sciences of
607 the United States of America*, 107(20), 9400–9405. <https://doi.org/10.1073/pnas.1000985107>

608 Grace, S. A., Rossell, S. L., Heinrichs, M., Kordsachia, C., & Labuschagne, I. (2018). Oxytocin and brain
609 activity in humans: A systematic review and coordinate-based meta-analysis of functional MRI
610 studies. *Psychoneuroendocrinology*, 96, 6–24. <https://doi.org/10.1016/j.psyneuen.2018.05.031>

611 Guastella, A. J., Einfeld, S. L., Gray, K. M., Rinehart, N. J., Tonge, B. J., Lambert, T. J., & Hickie, I. B. (2010).
612 Intranasal Oxytocin Improves Emotion Recognition for Youth with Autism Spectrum Disorders.
613 *Biological Psychiatry*, 67(7), 692–694. <https://doi.org/10.1016/j.biopsych.2009.09.020>

614 Guastella, A. J., & Hickie, I. B. (2016). Oxytocin Treatment, Circuitry, and Autism: A Critical Review of the
615 Literature Placing Oxytocin into the Autism Context. *Biological Psychiatry*, 79(3), 234–242.
616 <https://doi.org/10.1016/j.biopsych.2015.06.028>

617 Guastella, A. J., Hickie, I. B., McGuinness, M. M., Otis, M., Woods, E. A., Disinger, H. M., Chan, H. K., Chen,
618 T. F., & Banati, R. B. (2013). Recommendations for the standardisation of oxytocin nasal
619 administration and guidelines for its reporting in human research. *Psychoneuroendocrinology*,
620 38(5), 612–625. <https://doi.org/10.1016/j.psyneuen.2012.11.019>

621 Guastella, A. J., & MacLeod, C. (2012). A critical review of the influence of oxytocin nasal spray on social
622 cognition in humans: Evidence and future directions. *Hormones and Behavior*, 61(3), 410–418.
623 <https://doi.org/10.1016/j.yhbeh.2012.01.002>

624 Hess, U., & Fischer, A. (2014). Emotional mimicry: Why and when we mimic emotions. *Social and
625 Personality Compass*, 8(2), 45–57. [https://www.mendeley.com/research-papers/emotional-
626 mimicry-we-mimic-
627 emotions/%0Ahttp://eds.a.ebscohost.com/eds/pdfviewer/pdfviewer?vid=3&sid=07ccf35d-0924-
628 40b0-8cee-f18a54bc9951%40sessionmgr4007](https://www.mendeley.com/research-papers/emotional-mimicry-we-mimic-emotions/%0Ahttp://eds.a.ebscohost.com/eds/pdfviewer/pdfviewer?vid=3&sid=07ccf35d-0924-40b0-8cee-f18a54bc9951%40sessionmgr4007)

629 Horta de Macedo, L. R., Zuardi, A. W., Machado-de-Sousa, J. P., Chagas, M. H. N., & Hallak, J. E. C. (2014).
630 Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in
631 a facial emotion matching task. *Psychiatry Research*, 220(1–2), 125–128.
632 <https://doi.org/10.1016/j.psychres.2014.07.082>

633 Hovey, D., Martens, L., Laeng, B., Leknes, S., & Westberg, L. (2020). The effect of intranasal oxytocin on

634 visual processing and salience of human faces. *Translational Psychiatry*, 10(1).
635 <https://doi.org/10.1038/s41398-020-00991-3>

636 Hubble, K., Daughters, K., Manstead, A. S. R., Rees, A., Thapar, A., & Van Goozen, S. H. M. (2017).
637 Oxytocin Reduces Face Processing Time but Leaves Recognition Accuracy and Eye-Gaze
638 Unaffected. *Journal of the International Neuropsychological Society*, 23(1), 23–33.
639 <https://doi.org/10.1017/S1355617716000886>

640 Huffmeijer, R., Alink, L. R. A., Tops, M., Grewen, K. M., Light, K. C., Bakermans-Kranenburg, M. J., & van
641 IJzendoorn, M. H. (2013). The impact of oxytocin administration and maternal love withdrawal on
642 event-related potential (ERP) responses to emotional faces with performance feedback. *Hormones
643 and Behavior*, 63(3), 399–410. <https://doi.org/10.1016/j.yhbeh.2012.11.008>

644 Kaltwasser, L., Hildebrandt, A., Wilhelm, O., & Sommer, W. (2017). On the relationship of emotional
645 abilities and prosocial behavior. *Evolution and Human Behavior*, 38(3), 298–308.
646 <https://doi.org/10.1016/j.evolhumbehav.2016.10.011>

647 Kappenman, E. S., & Luck, S. J. (2016). Best Practices for Event-Related Potential Research in Clinical
648 Populations. *Biol Psychiatry Cogn Neurosci Neuroimaging*, 1(2), 110–115.
649 <https://doi.org/10.1016/j.bpsc.2015.11.007>.

650 Keech, B., Crowe, S., & Hocking, D. R. (2018). Intranasal oxytocin, social cognition and
651 neurodevelopmental disorders: A meta-analysis. *Psychoneuroendocrinology*, 87(September
652 2017), 9–19. <https://doi.org/10.1016/j.psyneuen.2017.09.022>

653 Kemp, A. H., & Guastella, A. J. (2011). The role of oxytocin in human affect: A novel hypothesis. *Current
654 Directions in Psychological Science*, 20(4), 222–231. <https://doi.org/10.1177/0963721411417547>

655 Kendrick, K. M., Guastella, A. J., & Becker, B. (2018). Overview of Human Oxytocin Research. In R.
656 Hurlemann & V. Grinevich (Eds.), *Behavioral pharmacology of neuropeptides: oxytocin* (Vol. 35, pp.
657 321–348). Springer International Publishing. <https://doi.org/10.1007/978-3-319-63739-6>

658 Korb, S., Malsert, J., Strathearn, L., Vuilleumier, P., & Niedenthal, P. (2016). Sniff and mimic - Intranasal
659 oxytocin increases facial mimicry in a sample of men. *Hormones and Behavior*, 84.

660 Kret, M. E., & De Gelder, B. (2012). A review on sex differences in processing emotional signals.
661 *Neuropsychologia*, 50(7), 1211–1221. <https://doi.org/10.1016/j.neuropsychologia.2011.12.022>

662 Lee, M. D., & Wagenmakers, E.-J. (2013). Bayesian model comparison. In *Bayesian Cognitive Modeling:
663 A practical course* (pp. 101–117). Cambridge University Press.
664 <https://doi.org/10.1017/cbo9781139087759.009>

665 Leknes, S., Wessberg, J., Ellingsen, D. M., Chelnokova, O., Olausson, H., & Laeng, B. (2013). Oxytocin
666 enhances pupil dilation and sensitivity to “hidden” emotional expressions. *Social Cognitive and*
667 *Affective Neuroscience*, 8(7), 741–749. <https://doi.org/10.1093/scan/nss062>

668 Leleu, A., Favre, E., Yailian, A., Fumat, H., Klamm, J., Amado, I., Baudouin, J., Franck, N., & Demily, C.
669 (2019). An implicit and reliable neural measure quantifying impaired visual coding of facial
670 expression: evidence from the 22q11.2 deletion syndrome. *Translational Psychiatry*.
671 <https://doi.org/10.1038/s41398-019-0411-z>

672 Lenth, R., Singmann, H., Love, J., Buerkner, P., & Herve, M. (2019). *emmeans: Estimated Marginal*
673 *Means, aka Least-Squares Means*. <https://doi.org/10.1080/00031305.1980.10483031>>.License

674 Leppanen, J., Ng, K. W., Tchanturia, K., & Treasure, J. (2017). Meta-analysis of the effects of intranasal
675 oxytocin on interpretation and expression of emotions. *Neuroscience and Biobehavioral Reviews*,
676 78, 125–144. <https://doi.org/10.1016/j.neubiorev.2017.04.010>

677 Lischke, A., Berger, C., Prehn, K., Heinrichs, M., Herpertz, S. C., & Domes, G. (2012). Intranasal oxytocin
678 enhances emotion recognition from dynamic facial expressions and leaves eye-gaze unaffected.
679 *Psychoneuroendocrinology*, 37(4), 475–481. <https://doi.org/10.1016/j.psyneuen.2011.07.015>

680 Liu-Shuang, J., Norcia, A. M., & Rossion, B. (2014). An objective index of individual face discrimination in
681 the right occipito-temporal cortex by means of fast periodic oddball stimulation.
682 *Neuropsychologia*, 52, 57–72. <https://doi.org/10.1016/j.neuropsychologia.2013.10.022>

683 Lopatina, O. L., Komleva, Y. K., Gorina, Y. V., Higashida, H., & Salmina, A. B. (2018). Neurobiological
684 aspects of face recognition: The role of oxytocin. *Frontiers in Behavioral Neuroscience*, 12, 1–11.
685 <https://doi.org/10.3389/fnbeh.2018.00195>

686 Lundqvist, D., Flykt, A., & Öhman, A. (1998). *The Karolinska Directed Emotional Faces - KDEF, CD ROM*
687 *from Department of Clinical Neuroscience, Psychology section*.

688 MacDonald, K., & MacDonald, T. M. (2010). The peptide that binds: A systematic review of Oxytocin and
689 its prosocial effects in humans. *Harvard Review of Psychiatry*, 18(1), 1–21.
690 <https://doi.org/10.3109/10673220903523615>

691 MacDonald, K. S. (2012). Sex, receptors, and attachment: A review of individual factors influencing
692 response to oxytocin. *Frontiers in Neuroscience*, 6, 1–8. <https://doi.org/10.3389/fnins.2012.00194>

693 Makeig, S., Bell, A. J., Jung, T.-P., & Sejnowski, T. J. (1995). Independent Component Analysis of
694 Electroencephalographic Data. In D. S. Touretzky, M. C. Mozer, & M. E. Hasselmo (Eds.), *Advances*
695 *in Neural Information Processing Systems 8* (pp. 145–151). MIT Press.

696 Martins, D. A., Mazibuko, N., Zelaya, F., Vasilakopoulou, S., Loveridge, J., Oates, A., Maltezos, S., Mehta,
697 M., Wastling, S., Howard, M., McAlonan, G., Murphy, D., Williams, S. C. R., Fotopoulou, A.,
698 Schuschnig, U., & Paloyelis, Y. (2020). Effects of route of administration on oxytocin-induced
699 changes in regional cerebral blood flow in humans. *Nature Communications*, *11*(1), 1–16.
700 <https://doi.org/10.1038/s41467-020-14845-5>

701 McIntosh, D. N. (1996). Facial feedback hypotheses: Evidence, implications, and directions. *Motivation*
702 *and Emotion*, *20*(2), 121–147. <https://doi.org/10.1007/BF02253868>

703 Mierop, A., Mikolajczak, M., Stahl, C., Béna, J., Luminet, O., Lane, A., & Corneille, O. (2020). How Can
704 Intranasal Oxytocin Research Be Trusted? A Systematic Review of the Interactive Effects of
705 Intranasal Oxytocin on Psychosocial Outcomes. *Perspectives on Psychological Science*, *15*(5), 1228–
706 1242. <https://doi.org/10.1177/1745691620921525>

707 Morey, R. D., Rouder, J. N., Jamil, T., Urbanek, S., Forner, K., & Ly, A. (2018). *BayesFactor: Computation*
708 *of Bayes Factors for Common Designs*. [https://cran.r-](https://cran.r-project.org/web/packages/BayesFactor/index.html)
709 [project.org/web/packages/BayesFactor/index.html](https://cran.r-project.org/web/packages/BayesFactor/index.html)

710 Naja, W. J., & Aoun, M. Pietro. (2017). Oxytocin and Anxiety Disorders: Translational and Therapeutic
711 Aspects. *Current Psychiatry Reports*, *19*(10). <https://doi.org/10.1007/s11920-017-0819-1>

712 Norcia, A. M., Appelbaum, L. G., Ales, J. M., Cottareau, B. R., & Rossion, B. (2015). The steady-state visual
713 evoked potential in vision research: a review. *Journal of Vision*, *15*(6), 1–46.
714 <https://doi.org/10.1167/15.6.4.doi>

715 Palermo, R., O’Connor, K. B., Davis, J. M., Irons, J., & McKone, E. (2013). New Tests to Measure Individual
716 Differences in Matching and Labelling Facial Expressions of Emotion, and Their Association with
717 Ability to Recognise Vocal Emotions and Facial Identity. *PLoS ONE*, *8*(6).
718 <https://doi.org/10.1371/journal.pone.0068126>

719 Pavarini, G., Sun, R., Mahmoud, M., Cross, I., Schnall, S., Fischer, A., Deakin, J., Ziauddeen, H., Kogan, A.,
720 & Vuillier, L. (2019). The role of oxytocin in the facial mimicry of affiliative vs. non-affiliative
721 emotions. *Psychoneuroendocrinology*, *109*, 104377.
722 <https://doi.org/10.1016/j.psyneuen.2019.104377>

723 Pehlivanoglu, D., Myers, E., & Ebner, N. C. (2020). Tri-Phasic Model of Oxytocin (TRIO): A systematic
724 conceptual review of oxytocin-related ERP research. *Biological Psychology*, *154*, 107917.
725 <https://doi.org/10.1016/j.biopsycho.2020.107917>

726 Peled-Avron, L., Abu-Akel, A., & Shamay-Tsoory, S. (2020). Exogenous effects of oxytocin in five

727 psychiatric disorders: a systematic review, meta-analyses and a personalized approach through
728 the lens of the social salience hypothesis. *Neuroscience and Biobehavioral Reviews*, *114*, 70–95.
729 <https://doi.org/10.1016/j.neubiorev.2020.04.023>

730 Peltola, M. J., Strathearn, L., & Puura, K. (2018). Oxytocin promotes face-sensitive neural responses to
731 infant and adult faces in mothers. *Psychoneuroendocrinology*, *91*, 261–270.
732 <https://doi.org/10.1016/j.psyneuen.2018.02.012>

733 Poncet, F., Baudouin, J.-Y., Dzhelyova, M., Rossion, B., & Leleu, A. (2019). Rapid and automatic
734 discrimination between facial expressions in the human brain. *Neuropsychologia*, *129*, 47–55.
735 <https://doi.org/10.1016/j.neuropsychologia.2019.03.006>

736 Quintana, D. S., Lischke, A., Grace, S., Scheele, D., Ma, Y., & Becker, B. (2021). Advances in the field of
737 intranasal oxytocin research: lessons learned and future directions for clinical research. *Molecular*
738 *Psychiatry*, *26*(1), 80–91. <https://doi.org/10.1038/s41380-020-00864-7>

739 Quintana, D. S., Smerud, K. T., Andreassen, O. A., & Djupesland, P. G. (2018). Evidence for intranasal
740 oxytocin delivery to the brain: Recent advances and future perspectives. *Therapeutic Delivery*, *9*(7),
741 515–525. <https://doi.org/10.4155/tde-2018-0002>

742 Retter, T. L., & Rossion, B. (2016). Uncovering the neural magnitude and spatio-temporal dynamics of
743 natural image categorization in a fast visual stream. *Neuropsychologia*, *91*, 9–28.
744 <https://doi.org/10.1016/j.neuropsychologia.2016.07.028>

745 Rimmele, U., Hediger, K., Heinrichs, M., & Klaver, P. (2009). Oxytocin makes a face in memory familiar.
746 *Journal of Neuroscience*, *29*(1), 38–42. <https://doi.org/10.1523/JNEUROSCI.4260-08.2009>

747 Rossion, B., Prieto, E. A., Boremanse, A., Kuefner, D., & Van Belle, G. (2012). A steady-state visual evoked
748 potential approach to individual face perception: Effect of inversion, contrast-reversal and
749 temporal dynamics. *NeuroImage*, *63*(3), 1585–1600.
750 <https://doi.org/10.1016/j.neuroimage.2012.08.033>

751 Schulze, L., Lischke, A., Greif, J., Herpertz, S. C., Heinrichs, M., & Domes, G. (2011). Oxytocin increases
752 recognition of masked emotional faces. *Psychoneuroendocrinology*, *36*(9), 1378–1382.
753 <https://doi.org/10.1016/j.psyneuen.2011.03.011>

754 Shahrestani, S., Kemp, A. H., & Guastella, A. J. (2013). The impact of a single administration of intranasal
755 oxytocin on the recognition of basic emotions in humans: A meta-analysis.
756 *Neuropsychopharmacology*, *38*(10), 1929–1936. <https://doi.org/10.1038/npp.2013.86>

757 Shamay-Tsoory, S. G., & Abu-Akel, A. (2016). The Social Salience Hypothesis of Oxytocin. *Biological*

- 758 *Psychiatry*, 79(3), 194–202. <https://doi.org/10.1016/j.biopsych.2015.07.020>
- 759 Shamay-Tsoory, S. G., Fischer, M., Dvash, J., Harari, H., Perach-Bloom, N., & Levkovitz, Y. (2009).
760 Intranasal Administration of Oxytocin Increases Envy and Schadenfreude (Gloating). *Biological*
761 *Psychiatry*, 66(9), 864–870. <https://doi.org/10.1016/j.biopsych.2009.06.009>
- 762 Shilling, P. D., & Feifel, D. (2016). Potential of Oxytocin in the Treatment of Schizophrenia. *CNS Drugs*,
763 30(3), 193–208. <https://doi.org/10.1007/s40263-016-0315-x>
- 764 Singmann, H., Bolker, B., Westfall, J., Aust, F., & Ben-Shachar, M. S. (2020). *Package ‘afex’ R topics*
765 *documented* : (Vol. 4).
- 766 Striepens, N., Kendrick, K. M., Hanking, V., Landgraf, R., Wüllner, U., Maier, W., & Hurlemann, R. (2013).
767 Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal
768 administration in humans. *Scientific Reports*, 3, 1–5. <https://doi.org/10.1038/srep03440>
- 769 Tillman, R., Gordon, I., Naples, A., Rolison, M., Leckman, J. F., Feldman, R., Pelphrey, K. A., & McPartland,
770 J. C. (2019). Oxytocin enhances the neural efficiency of social perception. *Frontiers in Human*
771 *Neuroscience*, 13, 1–13. <https://doi.org/10.3389/fnhum.2019.00071>
- 772 Van der Donck, S., Dzhelyova, M., Vettori, S., Mahdi, S. S., Claes, P., Steyaert, J., & Boets, B. (2020). Rapid
773 neural categorization of angry and fearful faces is specifically impaired in boys with autism
774 spectrum disorder. *Journal of Child Psychology and Psychiatry*, 61(9), 1019–1029.
775 <https://doi.org/10.1111/jcpp.13201>
- 776 Van der Donck, S., Dzhelyova, M., Vettori, S., Thielen, H., Steyaert, J., Rossion, B., & Boets, B. (2019). Fast
777 Periodic Visual Stimulation EEG Reveals Reduced Neural Sensitivity to Fearful Faces in Children
778 with Autism. *Journal of Autism and Developmental Disorders*, 49(11), 4658–4673.
779 <https://doi.org/10.1007/s10803-019-04172-0>
- 780 Van IJzendoorn, M. H., & Bakermans-Kranenburg, M. J. (2012). A sniff of trust: Meta-analysis of the
781 effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to
782 out-group. *Psychoneuroendocrinology*, 37(3), 438–443.
783 <https://doi.org/10.1016/j.psyneuen.2011.07.008>
- 784 Vettori, S., Dzhelyova, M., Van der Donck, S., Jacques, C., Steyaert, J., Rossion, B., & Boets, B. (2020).
785 Frequency-Tagging Electroencephalography of Superimposed Social and Non-Social Visual
786 Stimulation Streams Reveals Reduced Saliency of Faces in Autism Spectrum Disorder. *Frontiers in*
787 *Psychiatry*, 11, 1–12. <https://doi.org/10.3389/fpsy.2020.00332>
- 788 Vettori, S., Van der Donck, S., Nys, J., Moors, P., Van Wesemael, T., Steyaert, J., Rossion, B., Dzhelyova,

789 M., & Boets, B. (2020). Combined frequency-tagging EEG and eye-tracking measures provide no
790 support for the “excess mouth/diminished eye attention” hypothesis in autism. *Molecular Autism*,
791 *11*(1), 1–22. <https://doi.org/10.1186/s13229-020-00396-5>

792 Wang, D., Yan, X., Li, M., & Ma, Y. (2017). Neural substrates underlying the effects of oxytocin: A
793 quantitative meta-analysis of pharmaco-imaging studies. *Social Cognitive and Affective*
794 *Neuroscience*, *12*(10), 1565–1573. <https://doi.org/10.1093/scan/nsx085>

795 Wigton, R., Radua, J., Allen, P., Averbeck, B., Meyer-Lindenberg, A., McGuire, P., Sukhi, S., & Fusar-Poli,
796 P. (2015). Neurophysiological effects of acute oxytocin administration: Systematic review and
797 meta-analysis of placebo-controlled imaging studies. *Journal of Psychiatry and Neuroscience*,
798 *40*(1), E1–E22. <https://doi.org/10.1503/jpn.130289>

799 Winterton, A., Westlye, L. T., Steen, N. E., Andreassen, O. A., & Quintana, D. S. (2021). Improving the
800 precision of intranasal oxytocin research. *Nature Human Behaviour*, *5*(1), 9–18.
801 <https://doi.org/10.1038/s41562-020-00996-4>

802 Wood, A., Rychlowska, M., Korb, S., & Niedenthal, P. (2016). Fashioning the Face: Sensorimotor
803 Simulation Contributes to Facial Expression Recognition. *Trends in Cognitive Sciences*, *20*(3), 227–
804 240. <https://doi.org/10.1016/j.tics.2015.12.010>

805 Xu, L., Ma, X., Zhao, W., Luo, L., Yao, S., & Kendrick, K. M. (2015). Oxytocin enhances attentional bias for
806 neutral and positive expression faces in individuals with higher autistic traits.
807 *Psychoneuroendocrinology*, *62*, 352–358. <https://doi.org/10.1016/j.psyneuen.2015.09.002>

808

809

810 Funding sources

811 This work was supported by the Research Foundation Flanders [grant G0C7816N, and the Excellence of
812 Science EOS grant G0E8718N (HUMVISCAT)]; and KU Leuven [grant C14/17/102].

813

814 Acknowledgements

815 The authors would like to thank all the participants who contributed to this study. The authors would
816 also like to thank Robine Hellemans for her help in conducting the study.

817

818 Conflict of interest

819 The authors declare no conflict of interest.

820

821 Reprints

822 Stephanie Van der Donck

823 Stephanie.vanderdonck@kuleuven.be

824

825 Figure captions

826 **Fig 1. Fast periodic visual stimulation oddball paradigm.** Neutral faces are presented sequentially at a
827 fast 6 Hz base rate, periodically interleaved with an expressive face – anger, fear, happiness – every fifth
828 image (1.2 Hz oddball rate). The identity of the faces changes every image. Stimuli shown here: AF02,
829 AF07, AF13, AF15, AF22, AF27, AF29.

830 **Fig 2. SNR spectra visualizing the expression-discrimination responses.** (Left) Visualization of the ROIs.
831 The three most leftward and three most rightward open circles constitute left and right occipito-
832 temporal (LOT and ROT) regions, respectively. The two central open circles constitute the medial-
833 occipital (MO) region. (Right) SNR spectra visualizing the expression-discrimination responses, recorded
834 over the LOT (upper row), MO (middle row) and ROT (lower row) regions, for each of the expressions
835 and both treatment conditions. The significant first seven harmonics (until 8.4 Hz) are displayed; the
836 dashed line indicates the 6 Hz base rate response.

837 **Fig 3. Expression-discrimination responses.** Scalp topographies and bar graphs of the summed baseline-
838 subtracted amplitudes evoked during both treatment sessions, displaying the mean expression-
839 discrimination responses for each of the three ROIs and for each facial expression. Error bars reflect
840 standard errors of the mean. No main nor interaction effect of treatment was evidenced. The emotion
841 by ROI interaction entails that medial-occipital (MO) responses for fearful and happy faces are
842 significantly larger than for angry faces, and that for angry faces, the MO responses are significantly
843 lower than the responses in the left and right occipito-temporal (LOT and ROT, respectively) regions.

844 ** < 0.01, *** < 0.001

845 Fig 4. General visual base rate responses. Scalp topographies and bar graphs of the summed baseline-
846 subtracted amplitudes evoked during both treatment sessions, displaying the general visual responses
847 to faces, for each of the three ROIs and for each facial expression. Error bars reflect standard errors of
848 the mean. The main effect of ROI is clearly visualized, with highest responses recorded over medial-
849 occipital (MO) sites, and higher responses in the right occipito-temporal (ROT) region versus the left

850 occipito-temporal (LOT) region, irrespective of the treatment condition or facial expression. * < 0.05,

851 *** < 0.001

852